News

Introductory remarks-CEO John Dennis

• Opening Comments describing SolAeroMed work over the past year, highlighting near-completion of S1226 Phase I safety studies and plans for Phase IIa trials this fall.
• Individual introductions of all present.

• Meeting opened

• Successful submission to Health Canada
• pre-clinical work accepted by Health Canada leading to approval of Phase I first in human clinical trial
• Phase I (safety) an important milestone and now completed and being written up
• Plan to submit results to Health Canada Q2/3 2014
• Plan to progress S1226 Phase II clinical trial to demonstrate efficacy

• Overview presentation of SolAeroMed financials
• Review of fiscal year
• Increase in grant funding and investments
• Updated compensation mechanism to reflect better tax management for both SolAeroMed and employees
• SolAeroMed maintained low burn rate and  intends to continue to do so as we progress through to Phase II clinical trials
• Additional investor funding sought $300-500k.
• New share purchases will be at $5/share ($10M valuation)
• Questioned on types of consultants & fees SolAeroMed engages.  Response provided by CEO as:
  • CRO for Phase I clinical trial (PharmaMedica)
  • Clinical Research writer to coordinate regulatory documents and Investigators Brochure
  • Regulatory CMC consultant who works for blend of cash and shares.
  • Vetrinary Toxicologist

• SolAeroMed has been improving its documentation and oversight to better position SolAeroMed for future partnering opporutnities.
• Discussion around benefits of public vs private company
  • SolAeroMed had opportunity to go public (TSX-V) in fall of 2014, but board and some management believed this premature and did not pursue.
• Discussion around pros and cons of public vs private company with consensus SolAeroMed should remain private for the time being.

• John reviewed the profiles of the existing board members, and their areas of focused support to SolAeroMed.
• Recommended we keep the same board for the next year.   All board members indicated wish to remain active in SolAeroMed:
  • Andy Clark
  • Phyllis Kane
  • Ian McAffer
  • Michael Flach
  • Gwyn Humphreys
  • Francis Green
  • John Dennis

• Motion by Michael Smith to approve existing board for another year.
• Seconded by Michael Flach
• Approved unanimously

• Motion by Michael Smith to adopt 2013 AGM minutes
• Seconded by Michael Flach
• Approved Unanimously

• Motion by Michael Flach
• Seconded by Michael Smith
• Approved unanimously

• Discussion about what a successful Phase IIa might mean for the potential future sale or worth of the company
  • Scenario that we could proceed as a new team with Angel, VC or go private
  • Scenarios that we could:
    •  sell company outright to medium or large Pharma
    • license the drugs to other companies and potential dividends to shareholders
  • SolAeroMed may consult with informed outside advisor to help negotiate potential deals, including provision of 3^rd party valuation of SolAeroMed.

• Dr John Butt gave a well received talk involving aspects of the history of ‘sudden deaths’ of young Albertans leading to the discovery S1226.
• The Prairie Provinces Asthma Mortality Study received the largest grant for the time through the Faculty of Medicine at the University of Calgary.

Review of need for S1226 asthma medication

Preclinical summary data

Phase I safety study

Associated indications for S1226 are being pursued in his Hospital lab facility.

• Richard Leigh was going to talk to upcoming Phase II clinical trials
  • He was unfortunately tied up in other meetings and dealing with a family medical emergency

• John thanked the shareholders for their continued support and observed that SolAeroMed was looking forward to reporting to shareholders through newsletters andwww.solaeromed.com